Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Human Amniotic Fluid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Organicell Starts Enrolling Long COVID Trial
Details : Zofin is an acellular, minimally manipulated product, derived from human amniotic fluid (HAF). This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from amniotic stem and e...
Brand Name : Zofin
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 17, 2022
Lead Product(s) : Human Amniotic Fluid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Exosome Based Therapeutic
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Beauty Health
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Exosomes are small membrane vesicles, which are among the most productive and conducive to wound healing and countering inflammation. The benefits will help treat the skin and address signs of aging when delivered as a booster through Hydrafacial’s exc...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 14, 2022
Lead Product(s) : Exosome Based Therapeutic
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Beauty Health
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Amniotic fluid derived microRNAs
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Zofin™ is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to SARS related to COVID-19 infection vs placebo.
Brand Name : Zofin
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 11, 2021
Lead Product(s) : Amniotic fluid derived microRNAs
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Zofin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Organicell Completes Enrollment for its Expanded Access Trial to Treat COVID-19 Patients with Zofin™
Details : The expanded access protocol provided access to the investigational product, Zofin, for patients in outpatient and inpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19 infection, or who are judged by a healthcare provider to b...
Brand Name : Zofin
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 22, 2021
Lead Product(s) : Zofin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Zofin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent.
Brand Name : Zofin
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 29, 2020
Lead Product(s) : Zofin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Zofin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Recipient : Regenerative Care Network
Deal Size : Undisclosed
Deal Type : Partnership
Details : Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicell’s lead therapeutic, Zofin™, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF.
Brand Name : Zofin
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 20, 2020
Lead Product(s) : Zofin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Recipient : Regenerative Care Network
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Zofin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Organicell Expanded Access To Treat COVID-19 Patients With ZofinTM
Details : Aside from Convalescent Plasma, Zofin, is the first reported acellular therapy which can be accessed under FDA’s approved expanded access program.
Brand Name : Zofin
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 29, 2020
Lead Product(s) : Zofin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Zofin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Recipient : Alternative Research Associates
Deal Size : Undisclosed
Deal Type : Partnership
Organicell Partnered With Alternative Research Associates
Details : The objective of the FDA phase I/II study is to investigate the safety and potential efficacy of perinatal sourced components for COVID-19. The study will enroll 20 patients and is expected to commence within the next two weeks.
Brand Name : Zofin
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 18, 2020
Lead Product(s) : Zofin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Recipient : Alternative Research Associates
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Organicell Flow
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Treatment with Organicell Flow resulted in a remarkable improvement in their clinical status, lung and renal function confirmed by follow up chest X-rays and lab data.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 27, 2020
Lead Product(s) : Organicell Flow
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Organicell Flow
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Organicell Announces FDA Approval of IND Application for the Treatment of SARS Due to COVID-19
Details : This trial will be the first randomized, double-blinded, placebo-controlled, phase I/II multi-center trial investigating the safety and efficacy of amniotic fluid sourced components for COVID-19.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 05, 2020
Lead Product(s) : Organicell Flow
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?